Lung function vs. symptoms: new study explores Nintedanib's Real-World impact

NCT ID NCT05151640

Completed Knowledge-focused Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Oct 01, 2025

Summary

This study followed 158 adults with chronic fibrosing interstitial lung disease (a type of progressive lung scarring) who were starting treatment with nintedanib. Researchers wanted to see if changes in lung function (measured by forced vital capacity) over 52 weeks were linked to changes in cough and breathlessness, as reported by patients on a questionnaire. The goal is to better understand how nintedanib affects symptoms in everyday life.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Acibadem City Clinic Tokuda University Hospital EAD

Sofia, 1407, Bulgaria
Biomedical Centers Sp. z o.o.

Warsaw, 00-844, Poland
Bronz Media SRL

Cluj-Napoca, 400015, Romania
Centre Hospitalier Universitaire Vaudois (CHUV)

Lausanne, 1011, Switzerland
Doctor 4 Sim Srl

Cluj-Napoca, 400428, Romania
Dr. Belaconi I. Ionela-Nicoleta - Medic Specialist Pneumologie

Bucharest, 32582, Romania
Dr. Fira-Mladinescu SRL

Timișoara, 300451, Romania
Dr. Ion Cantacuzino Clinical Hospital

Bucharest, 020475, Romania
Dr. Toma Claudia Lucia - Medic Primar Pneumologie

Bucharest, 41651, Romania
Fakultni Nemocnice Plzen

Pilsen, 30100, Czechia
HOCH Health Ostschweiz

Sankt Gallen, CH-9007, Switzerland
Hanna Jagielska Len IPL

Zielona Góra, 65-101, Poland
IPL Michał Krawczyk

Lodz, 94-053, Poland
Iasis Srl

Timișoara, 300708, Romania
Indywidualna SPL Małgorzata Noceń-Piskorowska

Szczecin, 70-205, Poland
Medical Military Academy MHAT Sofia

Sofia, 1606, Bulgaria
Mirosław Nęcki SPL

Krakow, 31-618, Poland
Nemocnice AGEL Novy Jicin a.s.

Nový Jičín, 74101, Czechia
PFI Ramazan Ana-Maria

Constanța, 900377, Romania
Pneumo Research Srl

Moşniţa Nouă, 307285, Romania
Prywatna Praktyka Lekarska Paweł Piesiak

Wroclaw, 50-521, Poland
Sc Pneumo Clinic Dantes Srl

Constanța, 900629, Romania
Somed Cr Sp. z o.o. sp.k.

Lodz, 90-368, Poland
Spital De Pneumologie Dr. Lavinia Davidescu S.R.L.

Oradea, 410155, Romania
Strambu I. Irina-Ruxandra - Activitate Medicala

Bucharest, 10991, Romania
Szpital Uniwersytecki Nr 2 Im Dr Jana Biziela W Bydgoszczy

Bydgoszcz, 85-168, Poland
Thomayer University Hospital

Prague, 140 59, Czechia
University Hospital Brno

Brno, 625 00, Czechia
University Hospital Brno

Brno, 62500, Czechia
University Hospital Ostrava

Ostrava-Poruba, 708 52, Czechia
Universitätsspital Basel

Basel, CH - 4031, Switzerland

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Nintedanib

What this could lead to

If successful, this could help doctors better understand how nintedanib affects symptoms like cough and breathlessness in people with progressive lung scarring.

What could go wrong

This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients with this condition.

Conditions

The condition(s) this trial relates to.

idiopathic pulmonary fibrosis interstitial lung disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG DISEASES, INTERSTITIAL